A Clinical Study to Evaluate the effect of siddha medicine Eelai Erumal Chooranam in Patients with Swasakasam ( Bronchial Asthma )

SINGLE CENTRIC PHASE II OPEN CLINICAL TRIAL IN SWASAKASAM (BRONCHIAL ASTHMA) WITH SIDDHA MEDICINE EELAI ERUMAL CHOORANAM - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105176

Enrollment

Registered

2026-03-02

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

Intervention1: Eelai Erumal chooranam: 1 Part of each Ingredients - Purified Justicia adathoda Ocimum tenuiflorum Solanum procumbens Solanum xanthocarpum Wedelia chinensis Mukia maderaspatana Ocimum a

Eligibility

Inclusion criteria

Inclusion criteria: Moderate cases of Bronchial Asthma as Evaluated by Spirometry Assessment FEV1 FVC PEF 60 TO 80 Percentage Ratio of FEV1 and FVC Less than 0.75 - 0.80

Exclusion criteria

Exclusion criteria: AGE Greater than 50 YEARS Other systemic illness Vulnerable population Known case of Bronchiectasis and Pulmonary TB Subject who are unwilling or unable to comply with the trial protocol

Design outcomes

Primary

Measure	Time frame
Outcome is mainly assessed by Reduction in clinical symptoms after treatment The Outcome is to improve the baseline Spirometry parameter scores.Timepoint: 48 Days	—

Secondary

Measure	Time frame
Outcome is mainly assessed by Reduction in clinical symptoms after treatment The Outcome is to improve the baseline Spirometry parameter scores.Timepoint: 48 Days	—

Countries

India

Contacts

Public ContactDr U CHITRA

GOVERNMENT SIDDHA MEDICAL COLLEGE, ARUMBAKKAM, CHENNAI

mmsankar2000@gmail.com9445716802

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026